🇺🇸 FDA
Pipeline program

Brilaroxazine

RVP-30-001 RECOVER

Phase 3 small_molecule active

Quick answer

Brilaroxazine for Schizophrenia is a Phase 3 program (small_molecule) at REVIVA PHARMACEUTICALS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Indication
Schizophrenia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials